9th Jun 2025 11:04
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Monday.
----------
AIM - WINNERS
----------
Celadon Pharmaceuticals PLC, up 30% at 13.00 pence, 12-month range 3p-82.5p. Shortly before the market close on Friday, the cannabis-based medicines-focused pharmaceutical company reported that it continued to be engaged in talks with a finance provider. The provider concluded due diligence and "indicated he is in the process of making funds available". Celadon said: "The company continues to have limited working capital and its ability to continue to trade is fully dependent upon receiving funds from the new finance provider and continued creditor and stakeholder support. In the event the company cannot secure funds during the course of the next week, the directors will have to protect the interests of all stakeholders and the company will be placed into administration."
----------
Revolution Beauty Group PLC, up 12% at 8.11p, 12-month range 4.7p-25.5p. It confirms that Sports Direct owner Frasers Group is one of a number of parties eyeing a bid for the company. The London-based cosmetics retailer says Frasers Group is "one of a number of parties conducting due diligence" as part of the formal sale process announced in May. Revolution Beauty adds there can be no certainty that Frasers' interest will result in a firm offer for the company. On Saturday, Sky News reported that Frasers had approached Revolution Beauty about a potential offer for the company.
----------
AIM - LOSERS
----------
Cordel Group PLC, down 12% at 7.125p, 12-month range 4.22p-8.125p. It warns that full-year revenue will be lower than previously forecast. The London-based company, which uses artificial intelligence to supply transport corridor analytics, expects to report revenue in the range of GBP4.7 million and GBP5.0 million for the financial year to June 30. This would represent growth of up to 12% from GBP4.4 million a year prior. But Chief Executive John Davis says it will be "lower than forecast", despite the firm making "excellent strategic progress" in the financial year. While sales momentum has "recently recovered", the majority of the revenue from new contracts is now expected to be recognised in the next financial year, Davis adds.
----------
By Eric Cunha, Alliance News news editor
Comments and questions to [email protected]
Copyright 2025 Alliance News Ltd. All Rights Reserved.
Related Shares:
Celadon PharmaceuticalsRevolution BeautyCordel GroupFrasers Group